Swiss company Siegfried has seen an increase in sales, EBITDA and net profit in 2020 and expects its turnover to exceed CHF1bn this year. The firm is also looking to execute on its partnership with BioNTech on filling and packaging the firm’s COVID-19 vaccine.

The AAM has unveiled its policy priorities for sustainable access to generics and biosimilars for the newly elected US president Joe Biden’s administration and the 117th Congress. The association has also launched a new advocacy campaign called “Secure Our Meds,” kicking off with a report on “Securing Sustainable Markets.”

Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast. 

ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.

Japan’s Towa saw 4.6% growth in domestic sales in the first nine months of FY21, on the back of new launches, as the coronavirus pandemic had only a “minor” effect on its business. But while the firm’s launch schedule for new products remains unaffected so far, the company pointed out that there may be slight delays in product development plans going ahead.

Biocon Biologics has become the first biosimilar insulins company to partner with the International Diabetes Federation to help increase affordable access to insulin worldwide. The partnership was sealed at the start of centenary celebrations of the discovery of insulin.